Divergent response to PD-L1 inhibition in advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma

Martin Salzmann; Christoph Löser; Jessica C Hassel

doi:10.1111/ddg.15072

Divergent response to PD-L1 inhibition in advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma

J Dtsch Dermatol Ges. 2023 Jul;21(7):803-805. doi: 10.1111/ddg.15072. Epub 2023 Apr 17.

Authors

Martin Salzmann¹, Christoph Löser², Jessica C Hassel¹

Affiliations

¹ Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
² Department of Dermatology, Skin Tumor Center, Ludwigshafen Hospital, Ludwigshafen, Germany.

PMID: 37066606
DOI: 10.1111/ddg.15072

No abstract available

Keywords: Checkpoint inhibitor; Merkel cell carcinoma; cutaneous squamous cell carcinoma; electrochemotherapy; immunotherapy; talimogene laherparepvec.

Publication types

Letter

MeSH terms

B7-H1 Antigen
Carcinoma, Merkel Cell* / drug therapy
Carcinoma, Merkel Cell* / pathology
Carcinoma, Squamous Cell* / drug therapy
Humans
Melanoma* / pathology
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology

Substances

B7-H1 Antigen